JRCT ID: jRCT2080222329
Registered date:17/12/2013
Basic Information
Recruitment status | |
---|---|
Health condition(s) or Problem(s) studied | Solid tumor |
Date of first enrollment | 17/12/2013 |
Target sample size | 40 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : TAS-118 INN of investigational material : Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : (Food effect study)TAS-118 will be administered orally after breakfast or under fasting once per day at the 1st or the 2nd administration. Generic name etc : TAS-118 INN of investigational material : Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : (Dosage form comparison study)TAS-118 or S-1/LV will be administered orally under fasting once per day at the 1st or the 2nd administration. control material(s) Generic name etc : S-1, LV INN of investigational material : S-1:Tegafur, gimeracil, oteracil LV:folic acid Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : (Dosage form comparison study)S-1/LV will be administered orally under fasting once per day at the 1st or the 2nd administration. |
Outcome(s)
Primary Outcome | The plasma concentrations and each pharmacokinetic parameter. Each pharmacokinetic parameter will be calculated, and be compared. |
---|---|
Secondary Outcome | -Frequency of adverse events and adverse drug reactions. -Antitumor efficacy in a continuous administration period etc -Safety: Common Terminology Criteria for Adverse Events (CTCAE) -Efficacy: RECIST guideline |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | -Written consent to participate as a subject in this clinical study. -Capable of oral intake. -Histologically or cytologically confirmed to be a solid tumor. -Standard therapies are ineffective, or there is no generally accepted standard treatment. -At least 20 years of age at the time of informed consent. -Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1. |
Exclude criteria | -Unmanageable Diarrhea (e.g. watery stool, difficulty in controlling bowel movements despite the medication, grade 2 or higher, 5 stools or more per day). -Current or past severe lung disease (e.g. interstitial pneumonia, pulmonary fibrosis, or severe emphysema). -Any other active illness such as severe cardiac disease (e.g. myocardial infarction, angina pectoris, arrhythmia, or cardiac failure) that would preclude safe administration of study therapy at the time of randomization. Any of the following events within the 6 months prior to randomization: any episode of myocardial infarction or angina pectoris. QTc interval was >= 450 msec. -The diabetic patients who have poorly controlled despite the medication or severe diabetic complication. -Serious complications (e.g. serious enteritis, serious stomatitis, gastrointestinal ulceration/hemorrhage/perforation, ileus, renal failure, nephrosis syndrome, liver failure or cerebrovascular disorder). |
Related Information
Primary Sponsor | Taiho Pharmaceutical Co., Ltd. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Taiho Pharmaceutical Co., Ltd. |
Secondary ID(s) | JapicCTI-132379 |
Contact
Public contact | |
Name | |
Address | toiawase@taiho.co.jp |
Telephone | |
Affiliation | Taiho Pharmaceutical Co., Ltd. |
Scientific contact | |
Name | |
Address | toiawaseCD1@taiho.co.jp |
Telephone | |
Affiliation | Taiho Pharmaceutical Co., Ltd. |